Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-06-03
2008-06-03
O'Hara, Eileen B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S143100, C435S007100, C435S326000, C435S332000, C435S334000, C435S070210, C530S350000, C530S387100, C530S388100, C530S388220
Reexamination Certificate
active
07381412
ABSTRACT:
The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also relates to host cells that produce such antibodies or antigen-binding fragments, kits comprising such antibodies or antigen-binding fragments and methods of use for such antibodies and antigen-binding fragments.
REFERENCES:
patent: 5440021 (1995-08-01), Chantharapai et al.
patent: 5652133 (1997-07-01), Murphy
patent: 6329159 (2001-12-01), Andrew et al.
patent: 6503735 (2003-01-01), Wei et al.
patent: 6689570 (2004-02-01), Andrew et al.
patent: 6723520 (2004-04-01), Wang et al.
patent: 6884574 (2005-04-01), Andrew et al.
patent: 6936248 (2005-08-01), Andrew et al.
patent: 2002/0141991 (2002-10-01), Andrew et al.
patent: 2003/0018167 (2003-01-01), Wang et al.
patent: 2003/0022238 (2003-01-01), Andrew et al.
patent: WO 97/48807 (1997-12-01), None
patent: WO 98/01557 (1998-01-01), None
patent: WO 98/32858 (1998-07-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Attwoo, Science 2000; 290:471-473.
Skolnick et al. ,Trends in Biotech. 2000; 18(1):34-39.
Metzler et al., Nature Structural Biol. 1997; 4:527-531.
Yoshida, R., et al., “Molecular Cloning of a Novel Human CC Chemokine EBI1-ligand Chemokine That is a Specific Functional Ligand for EBI1, CCR7,”The Journal of Biological Chemistry, 272(21): 13803-13809 (1997).
Baba, M., et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-Directed CC Chemokine LARC,”The Journal of Biological Chemistry, 272(23): 14893-14898 (1997).
Imai, T., et al., “The T Cell-Directed CC Chemokine TARC is Highly Specific Biological Ligand for CC Chemokine Receptor 4,”The Journal of Biological Chemistry, 272(23): 15036-15042 (1997).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3,”The Journal of Biological Chemistry, 271(13): 7725-7730 (1996).
Vicari, A.P., et al., “TECK: A Novel CC Chemokine Specifically Expressed by Thymic Dendritic Cells and Potentially Involved in T Cell Development,”Immunity, 7:291-301 (1997).
Damon, I., et al., “Broad Spectrum Chemokine Antagonistic Activity of a Human Poxvirus Chemokine Homolog,”Proc. Natl. Acad. Sci. USA, 95:6403-6407 (1998).
O'Garra, A., et al, “T-cell Subsets: Chemokine Receptors Guide the Way,”Current Biology, 8:R646-R649 (1998).
Kim, C.H., et al., “Chemokines: Signal Lamps for Trafficking of T and B Cells for Development and Effector Function,”J. Leukoc. Biol., 65:6-15 (1999).
Murphy, P.M., “The Molecular Biology of Leukocyte Chemoattractant Receptors,”Annu. Rev. Immunol., 12:593-633 (1994).
Zlotnik, A., et al., “Recent Advances in Chemokines and Chemokine Receptors,”Critical Reviews™ in Immunology, 19:1-47 (1999).
Nomiyama, H., et al., “The Human CC Chemokine TECK (SCYA25) Maps to Chromosome 19p13.2,”Genomics, 51:311-312 (1998).
Vicari, A.P., et al., “TECK: A Novel CC Chemokine Associated with T-Cell development,”J. Allergy Clin. Immunol., 99(1):S246, Abstract No. 1003, (1997).
Combadiere, C., et al., “Cloning and Functional Expression of Two Human CC Chemokine Receptors,”FASEB J. 10(6):A1093 Abstract No. 545, (1996).
Gao, J.-L., et al., “Cloning and Expression of the Mouse MIP-1α Receptor Gene and Two Related Genes,”9th International Congress of Immunology, p. 108, Abstact No. 637 (1995).
GenBank Accession No. U45982, “Human G Protein Coupled Receptor GPR-9-6 Gene, Complete CDS,” (1996).
Zaballos, A., et al., “Cutting Edge: Identification of the Orphan Chemokine Receptor GPR-9-6 as CCR9, the Receptor for the Chemokine TECK,”J. Immunol.,162(10):5671-5675 (1999).
Chuntharapai, A. and Kim, K.J., “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Locati M. et al., “Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS,”Annu. Rev. Med. 50:425-440 (1999).
Zabel, B.A. et al., “Human G Protein-coupled Receptor GPR-9-6/CC Chemokine Receptor 9 is Selectively Expressed on Intestinal Homing T Lymphoctyes, Mucosal Lymphocytes, and Thymocytes and is Required for Thymus-expressed Chemokine-mediated Chemotaxis,”J. Exp. Med 190(9):1241-1255 (1999).
Swissprot Database, Accession No.: P51686, “Portable G-Protein-Coupled Receptor GPR-9-6” [online], Oct. 1996
Nibbs, R.J.B., et al., “Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6,”J. Biol. Chem., 272(51):32078-32083 (1997).
Murphy, P.M., et al., “International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors,”Pharmacol. Rev., 52(1):145-176 (2000).
Youn, B-S, et al., “TECK, an Efficacious Chemoattractant for Human Thymocytes, Uses GPR-9-6/CCR9 as a Specific Receptor,”Blood, 94(7):2533-2536 (1999).
Attwood, T.K., “The Babel of Bioingormatics,”Science, 290:471-473 (2000).
MOLT-13, ACC 436, [online] Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 2003 [retrieved on Mar. 4, 2003]. Retrieved from the Internet:<URL: www.dsmz.de/dsmzhome.htm.
Huang, Z., “Structural Chemistry and Therapeutic Intervention of Protein-Protein Interactions in Immune Response, Human Immunodeficiency Virus Entry and Apoptosis,”Pharmacology&Therapeutics, 86:201-215 (2000).
Zlotnick, et al., “Chemokines: A New Classification System and Their Role in Immunity,”Immunity, 12:121-127 (2000).
Mackay, C., “Chemokines: Immunology's High Impact Factors,”Nature Immunology, 2(2):95-101 (2001).
ATCC Accession No.: CRL-1582, ATCC Cell Lines and Hybridomas, p. 149, 7thEdition, 1992 American Type Culture Collection, current address 10801 University Boulevard, Manassas, VA 20110-2209.
Hoffmann, J.C., et al., “Animal Models of Inflammatory Bowel Disease: An Overview,”Pathobiology, 3(70): 121-130 (2002).
Taneja, V. and David, C.S., “Lessons from Animal Models for Human Autoimmune Diseases,”Nature Immunology 2(9): 781-784 (2001).
Andrew David P.
Ponath Paul D.
Zabel Brian A.
Hamilton Brook Smith & Reynolds P.C.
Kim Yunsoo
Millennium Pharmaceuticals Inc.
O'Hara Eileen B.
LandOfFree
Anti-TECK antibodies and methods of use therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-TECK antibodies and methods of use therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TECK antibodies and methods of use therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797273